Long-term Aspirin use Reduces the Incidence of Digestive Cancers by up to 47%, Study Presented at UEG Week Reveals

Food and Healthcare Press Releases Tuesday October 31, 2017 08:00
BARCELONA, Spain--31 Oct--PRNewswire/InfoQuest
The long-term use of aspirin has been shown to significantly reduce the incidence of digestive cancers, new research presented today at the 25th UEG Week have found[1].

In a study involving over 600,000 people, researchers compared patients who were prescribed aspirin over a long period (for at least six months, average duration of aspirin prescribed was 7.7 years) with non-aspirin users and assessed the incidences of a number of cancers. Those prescribed with aspirin showed a 47% reduction in liver and oesophageal cancer incidence, a 38% reduction in gastric cancer incidence, a 34% reduction in pancreatic cancer incidence and a 24% reduction in colorectal cancer incidence.

Digestive cancers account for almost a quarter of cancer cases in Europe[2]. Colorectal, gastric and pancreatic cancer are within the top five cancer killers throughout the continent, with digestive cancers representing 30.1% of cancer deaths.

Aspirin is used across the globe to treat a number of health conditions, ranging from short-term pain relief to long-term prescriptions. Whilst the use of aspirin is subject to continued debate within the medical community, a recent study found that patients who stopped taking aspirin were 37% more likely to have an adverse cardiovascular event, such as a heart attack or stroke, than those who continued with their prescription[3].

Reduction in incidence of cancer by
Cancer Site                   aspirin user
(compared with non-user)
Liver                         47%
Oesophageal                       47%
Gastric                         38%
Pancreatic                       34%
Colorectal                       24%
Table 1 - Reduction in incidence of digestive cancer

The effect of long-term use of aspirin on cancer incidence was also examined for cancers outside of the digestive system. Here, a significant reduction was shown for some (leukaemia, lung and prostate) but not all (breast, bladder, kidney and multiple myeloma) cancers.

Lead researcher, Professor Kelvin Tsoi from the Chinese University of Hong Kong, presented the study today at the 25th UEG Week in Barcelona. "The findings demonstrate that the long-term use of aspirin can reduce the risk of developing many major cancers," commented Professor Tsoi. "What should be noted is the significance of the results for cancers within the digestive tract, where the reductions in cancer incidence were all very substantial, especially for liver and oesophageal cancer."

References:

1. Tsoi, K. et al. Long-term use of aspirin is more effective to reduce the incidences of gastrointestinal cancers than non-gastrointestinal cancers: A 10-year population based study in Hong Kong. Presented at UEG Week Barcelona 2017.

2. GLOBOCAN, IARC (2012). Section of Cancer Surveillance.
3. Stopping aspirin treatment raises cardiovascular risk by over a third (2017). Available at: https://www.medicalnewstoday.com/articles/319541.php
Source: United European Gastroenterology (UEG)

Latest Press Release

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose disease progressed after...

PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the...

After multiple failed procedures at other medical institutions, Colorado man successfully treated for Atrial Fibrillation at Texas Cardiac Arrhythmia Institute at St. David#s Medical Center

"I was thinking I was on top of the world," Wiseman said. "I was keeping myself in shape. I was taking care of myself mentally and physically. My relationship was solid." Then, during a routine medical exam while serving in the military in California,...

World#s Leading Health Organizations Release Third Edition of Widely Used Resource on Family Planning

Global Handbook Gives Health-Care Providers Accurate and Practical Guidance for Counseling Clients Family planning is considered a development "best buy" and a life-saving intervention for millions of women and girls. Crucial to the success of family...

ไฟเซอร์ ประเทศไทย สนับสนุนงานประชุมวิชาการด้านโรคมะเร็ง

แผนกมะเร็งวิทยาของบริษัท ไฟเซอร์ (ประเทศไทย) จำกัด (Pfizer Oncology) ให้การสนับสนุนการจัดงานประชุมวิชาการ 'The 5th Ramathibodi-Mayo Clinic Joint Conference: Best Practice in Oncology 2018' ช่วง Lunch Symposium' ในหัวข้อ Continuum of care for ALK positive...

Related Topics